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The thermal behavior of two polymorphic forms of rifampicin was studied by DSC and TG/DTG. The 
thermoanalytical results clearly showed the differences between the two crystalline forms. Polymorph 
I was the most thermally stable form, the DSC curve showed no fusion for this species and the thermal 
decomposition process occurred around 245 °C. The DSC curve of polymorph II showed two consecutive 
events, an endothermic event (T
peak
 = 193.9 °C) and one exothermic event (T
peak
 = 209.4 °C), due to 
a melting process followed by recrystallization, which was attributed to the conversion of form II to 
form I. Isothermal and non-isothermal thermogravimetric methods were used to determine the kinetic 
parameters of the thermal decomposition process. For non-isothermal experiments, the activation 
energy (E
a
) was derived from the plot of Log β vs 1/T, yielding values for polymorph form I and II of 
154 and 123 kJ mol-1, respectively. In the isothermal experiments, the E
a
 was obtained from the plot of 
lnt vs 1/T at a constant conversion level. The mean values found for form I and form II were 137 and 
144 kJ mol-1, respectively.
Uniterms: Rifampicin. Tuberculosis. Thermal analysis. Thermal decomposition. Kinetic analysis.
O comportamento térmico de duas formas polimórficas da rifampicina foi estudado por DSC e TG/DTG. 
Os resultados termoanalíticos mostraram claramente as diferenças entre as duas formas cristalinas. O 
polimorfo I é a forma mais estável termicamente, a curva DSC não mostrou a fusão dessa espécie e o 
processo de decomposição térmica ocorreu próximo a 245 oC. A curva DSC do Polimorfo II apresentou 
dois eventos consecutivos, um endotérmico (T
pico
 = 193,9 oC) e outro exotérmico (T
pico
 = 209,4 oC), 
devido à fusão seguida de recristalização, a qual foi atribuída à conversão da forma II à forma I. Métodos 
termogravimétricos isotérmicos e não-isotérmicos foram empregados para determinar os parâmetros 
cinéticos do processo de decomposição térmica. Para experimentos não-isotérmicos, a energia de ativação 
(E
a
) foi obtida a partir do gráfico de Log β vs 1/T, e os valores 154 e 123 kJ mol-1 foram encontrados, 
respectivamente, para os polimorfos I e II. Para os experimentos isotérmicos, a E
a
 foi obtida a partir do 
gráfico de lnt vs. 1/T a um nível de conversão constante. O valor médio encontrado foi 137 e 144 kJ mol-1, 
respectivamente, para a forma I e forma II.
Unitermos: Rifampicina. Tuberculose. Análise Térmica. Decomposição térmica. Análise cinética.
INTRODUCTION
Thermal Analysis (TA) is the study of the relation-
ship between a sample property and its temperature as 
the sample is heated or cooled in a controlled manner 
[Rouquerol et al., 2007]. The most widely used techniques 
for application in the pharmaceutical area are thermogra-
vimetry (TG), differential thermal analysis (DTA) and 
differential scanning calorimetry (DSC) (Ford, Timmins, 
1989; Matos et al., 2009).
Thermogravimetry measures variations in mass as a 
function of time and/or temperature. The curves obtained 
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give information about the composition and thermal sta-
bility of the sample, the intermediate products and end 
residue. The derivative thermogravimetric curve (DTG) 
is the first derivative of the TG curve. In this curve, the 
degrees corresponding to variations in mass used by the 
TG curve are replaced with peaks which determine propor-
tional areas corresponding to mass variations. The DTG 
curve presents the same information as the TG; however, 
it allows for separation of the superimposed reactions, 
since the subtle inflections of TG are emphasized. Thus, 
the temperatures corresponding to the beginning and end 
of the reaction can be measured more precisely. Also, it 
aids in the calculation of mass variation in the case of reac-
tion overlap, since using only the TG curve it is difficult 
to define the start and end of the reaction.
The DSC, derived from the DTA technique, mea-
sures the difference in energy provided to the substance 
and a reference material (thermally stable), as a function of 
temperature, while both are being subjected to a controlled 
temperature program. When the sample undergoes a tem-
perature alteration due to an endothermic or exothermic 
reaction in response to heating or cooling, the differential 
heat flux necessary to keep the sample and reference at 
the same temperature can be measured. The temperature 
difference between the sample and reference material is 
due to chemical reactions (decomposition, combustion), 
change of state (melting, sublimation) or crystalline tran-
sitions. These events are expressed in the form of peaks. 
Regarding heat flux DSC, the upward peaks represent 
exothermic events, while the downward peaks are charac-
teristic of endothermic events. In the case of second-order 
transitions, there are changes in the baseline without peaks. 
For example, the glass transition (T
g
) is evidenced on the 
DSC curve as a change in baseline in the endothermic 
direction.
The area under the peak represents the change in 
enthalpy, DH, undergone by the sample (heat absorbed or 
released during the thermal reaction).
Ideally, the information from TG/DTG and DSC 
should be combined to enable optimal characterization 
of the materials. Although the TG/DTG detect all types 
of thermal reactions in terms of variations in mass, the 
DSC also detects reactions which may or may not be as-
sociated with loss of mass, such as physical phenomena. 
For example, a change in physical state (fusion) can be 
unequivocally attributed from the DSC curve if losses 
in mass reactions are not found in the same temperature 
range on TG/DTG curves. In most cases, interpretation 
of thermal reactions is difficult without superposition of 
the TG/DTG and DSC curves obtained under the same 
experimental conditions.
In the case of drugs and medicines, the TG/DTG 
and DSC techniques allow evaluation and/or comparison 
of thermal stabilities of pharmaceutical materials, the 
acquisition of data on drug/excipient compatibility for 
the pre-formulation studies, and determination of kinetic 
parameters (activation energies, frequency factor, and re-
action order). This information is useful in pharmaceutical 
quality control, development of pharmaceutical products 
and for evaluation of quality of pharmaceutical products 
from technologic parameters (Venkataram et al., 1995; 
Araújo et al., 2003; Giron, 1995; Cides et al., 2006).
According to the Panamerican Health organiza-
tion, 50% of the cases of tuberculosis in the Americas are 
found in Peru and Brazil. In 2004, the Ministry of Health 
estimated that some 50 million Brazilians were infected 
with Mycobacterium tuberculosis, which ranked Brazil 
16th among the 22 countries with the highest levels of 
tuberculosis (WHO, 2006).
The discovery of rifamycins in the late 1950s led to 
the synthesis of rifampicin in 1965, and its introduction as 
a therapy in 1968 (Bujnowski et al., 2003).
Rifampicin is a semi-synthetic antibiotic derived 
from the rafamycin B family, produced by strains of 
Nocardia (Streptomyces) mediterranei. It has a wide 
spectrum antibacterial action including activity against 
various strains of Mycobacterium. It inhibits the activity 
of the DNA dependent RNA polymerase enzyme through 
the formation of a stable complex with this enzyme. This 
abolishes the synthesis of bacterial RNA. It functions in 
intra and extracellular microorganisms and in bacteria in 
latent states or when undergoing the process of division 
(Zhang, 2005; Bacchi et al., 1998).
Rifampicin has been included in the primary list of 
essential medications by the World Health Organization 
and remains the principal drug in the treatment of tuber-
culosis (Agrawal et al., 2004; WHO, 2007).
The introduction of rifampicin, in combination with 
isoniazid, into the therapy for tuberculosis reduced the 
length of treatment necessary from 18-24 months to 6-9 
months (Zhang, 2005; Saltini, 2006).
The Minimal Inhibitory Concentration (MIC), from 
0.25 to 0.50 mg/mL, was defined as the lowest level among 
pharmaceutical drugs which inhibits growth of Mycobac-
terium tuberculosis (Carvalho et al., 2007).
WHO recommendations for the treatment of tubercu-
losis are based on rifampicin in association with other drugs, 
mainly isoniazid, pyrazinamide and ethambutol, known as 
tuberculostatic drugs of first choice, in order to avoid the 
emergence of strains of resistant bacteria. (WHO, 2007).
Rifampicin is officially designated as 2,7-(epo-
xypentadeca [1,11,13] trienimino)naphtho[2,1-b]furan-
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1,11(2H)-dione,5,6,9,17,19,21-hexahydroxy-23-methoxy-
2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-pipe-
razinyl)formimidoyl]-2,7-acetate by the IUPAC. 
However, in the literature it is more commonly 
known as 3-[[(4-methyl-1-piperazinyl)imino]methyl] ri-
famycin SV, according to the original nomenclature of the 
rifamycins (Gallo, Radaelli, 1976). The molecular formula 
is C
43
H
58
N
4
O
12
, with a molecular mass of 822.94 g/mol 
(62.76% =C; 7.10% =H; 6.81 %= N and 23.33%= O) and 
its molecular structure is shown in Figure 1.
Rifampicin is slightly soluble in water and its solubili-
ty and stability varies according to pH due to its amphoteric 
nature. At a pH of 2, its solubility is 100 mg/mL, whereas at 
pH 5.3 this falls to 4.0 mg/mL, and at pH 7.5, the solubility 
is 2.8 mg/mL (Gallo, Radaelli, 1976). In acidic solutions, ri-
fampicin undergoes hydrolysis to yield 3-formyl-rifamycin 
and 1-amino 4-methylpiperazine. Under alkaline conditions 
(pH of 7.5 to 9.0) rifampicin will oxidize if oxygen is pre-
sent, becoming rifampicin-quinone. (Gallo, Radaelli, 1976; 
Singh et al., 2001). Maximum stability of rifampicin is 
reached in near-neutral solutions. The addition of ascorbic 
acid to the solution increases the solubility of rifampicin and 
decreases its oxidation (Gallo, Radaelli, 1976).
Rifampicin exists as a polymorph with two principal 
forms, I and II, and also in amorphous form (Pelliza et al., 
1977). Form I is the most stable, while form II is the most 
meta-stable. Besides these two principal forms, rifampi-
cin is found as a hydrate and solvate, which convert to 
amorphous form after removal of the solvent (Henwood 
et al., 2001). 
Recent studies have shown that the polymorphic 
forms I and II of rifampicin have different solubility in 
aqueous media (Henwood et al., 2001; Agrawal et al., 
2004). These differences in solubility in aqueous media 
could affect the absorption and bioavailability of the drug 
when in solid state for oral ingestion (Singh et al., 2001; 
Agrawal et al., 2004; Panchagnula, Agrawal, 2004).
The objective of this study was to employ TG/DTG 
and DSC to study the thermal behavior and decomposition 
kinetics of rifampicin polymorphs under isothermal and 
non-isothermal conditions.
MATERIAL AND METHODS
Material
Rifampicin samples were kindly provided by FURP 
(form I, batch 142/03 and form II, batch RR327273/0).
Methods
The DSC curves were obtained on a DSC-50 cell 
(Shimadzu) using aluminum crucibles with about 2 mg 
of sample, under dynamic N
2
 atmosphere (50 mL min-1) 
and heating rate (β) of 10 °C min-1 between 25 to 500 °C. 
The DSC cell was calibrated using indium (m.p. 156.6 °C, 
DH
fusion
 = 28.54 J g-1) and zinc (m.p. 419.6 °C).
The TG/DTG curves were obtained with a thermo-
balance model TGA-50 (Shimadzu) in the temperature 
range of 25-700 °C, using a platinum crucible with ap-
proximately 5 mg of sample in a dynamic air atmosphere 
(100 mL min-1) and β of 10 °C min-1. For the non-isother-
mal kinetic study of the thermal decomposition process 
for the two polymorphic forms of rifampicin, the Ozawa 
dynamic method was applied using the TG kinetic analysis 
program installed on Shimadzu data acquisition system. 
Six different β were used: 2.5, 5.0, 7.5, 10, 15 and 20 °C 
min–1 under dynamic air atmosphere (50 mL min–1).
Concerning the kinetic study by isothermic TG, five 
TG curves were obtained using the following experimental 
conditions: a) heating of the sample with β of 20 oC/min 
from room temperature up to T
isotherm
–10 oC; b) heating of 
the sample from T
isotherm
–10oC up to T
isotherm
 at 2 oC/min; c) 
at the temperature of the isotherm (T
isotherm
), the heating was 
kept constant until the initial mass of the sample was re-
duced by at least 10%. The T
isotherm
 elected for polymorph I 
were 200, 205, 210, 220 and 230 oC, given that the TG/DTG 
curves obtained (Figure 2) at 10 oC/min showed that ther-
mal decomposition of the sample began at a temperature 
of around 240 oC. Using the same criteria for polymor-
ph II, the T
isotherm
 chosen were 175, 180, 185, 190 and 
195 oC.
The infrared absorption spectra of the rifampicin 
polymorphs and the intermediates from the thermal de-
composition process were obtained using model MB102 
FIGURE 1 - Molecular structure of rifampicim [Agrawal et al., 
2004].
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equipment (Bomem) in the region of 4000 to 400 cm-1. 
KBr pellets containing small amount of the samples were 
prepared. The studies were done at the Laboratories of 
Analytic Center of the Chemistry Institute of the Univer-
sity of São Paulo.
RESULTS AND DISCUSSION
Thermal behavior of polymorphs I and II 
The TG/DTG and DSC curves of rifampicin poly-
morph I are shown in Figure 2. The TG/DTG curves in-
dicated that this crystalline form is thermally stable up to 
around 240 °C and that the thermal decomposition process 
occurred in two stages. The first stage occurred rapidly 
between 240 and 275 °C, with a mass loss of 19.5%. Ho-
wever, the second step occurred slowly between 275 and 
625 °C with gradual mass loss of around 80%. The resi-
dual amount of approximately 0.5% was partially derived 
from elementary carbon formed during the second step of 
the thermal decomposition. The thermal events observed 
on the DSC curve were exothermic and are according to 
mass losses evidenced on the TG/DTG curves. The first 
thermal decomposition was evidenced between 240 and 
295 °C (T
peak
 = 268 °C) and the second occurred between 
295 and 500 °C (T
peak
 = 400 °C).
The TG/DTG and DSC rifampicin polymorph 
II curves are shown in Figure 3. The TG/DTG curves 
indicated a crystalline form which is thermally stable 
up to around 195°C. The thermal decomposition pro-
cess occurred in three stages. The first occurred rapidly 
between 195 and 258°C with loss of mass of around 
11.9%, while the second occurred more slowly between 
258 and 440 °C with mass loss of 27.3%. Finally, the 
third stage occurred between 440 and 770 °C with mass 
loss of 59.5%. There was a small amount of residue 
of 1.2% which was partially derived from elementary 
carbon formed during the second and third step of the 
thermal decomposition. The thermal events observed on 
the DSC curve are according to mass losses evidenced 
on the TG/DTG curves. The DSC curve showed an en-
dothermic event with a heat variation starting at 160 ºC 
(T
peak
=193.9 °C), followed by three exothermic events 
(T
peak
= 209.4; 257.6 and 420.9 °C). The endothermic 
event which occurred at 193.9 ºC (T
peak
) is characteris-
tic of a melting process followed by recrystallization, 
which in turn is characterized by the exothermic event 
at 209.4 °C (T
peak
). The thermal decomposition process 
began with the heat liberated from recrystallization whi-
ch produces polymorph I and proceeded exothermally, 
as indicated on the DSC curve by the temperature peaks 
at 257.6 and 420.9 °C.
Comparison of the thermal behavior of 
polymorphic I and II 
From the overlap of the DSC curves of Figure 4, the 
differences between the two crystalline forms are clearly 
evident. On the DSC curve (a) of the polymorphic form I 
(curve a) , a smaller number of thermal events (only two) 
is observed. This form is more thermally stable. The DSC 
curve showed no fusion of the species, but the process of 
thermal decomposition began at approximately 245 oC 
(T
peak
 = 268.6 oC). On the other hand, on the DSC curve (b) 
of the polymorph II four thermal events are evident. The 
first is endothermic (T
peak
 = 193.9 °C) due to melting of 
species. The second event is exothermic and is attributed 
to a recrystallization (T
peak
 = 209.4 °C) and corresponds to 
conversion of polymorphic form II into polymorphic form 
I. The evidence indicates that a fraction of heat released in 
FIGURE 2 - TG/DTG and DSC curves obtained at 10 oC/min for 
the rifampicin sample (polymorph I).
FIGURE 3 - TG/DTG and DSC curves obtained at 10oC/min for 
the rifampicin sample (polymorph II).
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the process of recrystallization to polymorph I (curve b) is 
used to initiate the thermal decomposition of the material. 
This can be concluded because the T
peak
 (257.6 oC) of the 
exothermic event indicative of the first stage of thermal 
decomposition (curve b) is lower than the T
peak
 (268 oC) 
that is indicative of the start of thermal decomposition of 
polymorph I (curve a). The TG/DTG curves (Figures 2 
and 3) showed there is mass loss at the same temperature 
range where recrystallization occurs and this confirms that 
the thermal decomposition of the species occurs simulta-
neously with recrystallization. Other peaks observed at 
temperatures of 257.6 oC and 420.9 oC (curve b) are due 
to thermal decomposition of polymorph I generated from 
polymorph II.
Kinetics of thermal decomposition of polymorphs 
I and II by non-isothermal TG
According to the OZAWA, 1965, several methods 
are proposed for obtaining kinetic parameters from ther-
mogravimetric data. There are a variety of relationships 
with particular models in differential and integral for-
ms. Specifically, the method described by Ozawa is 
based on the integral calculations from the equation of 
Arrhenius.
 k(T) = A.e –Ea/RT  (Equation 4)
where A is the frequency factor, R is the general constant 
of gases (8.314 J mol-1 K-1), E
a
 the activation energy and 
T the absolute temperature.
To study the thermal decomposition kinetics for non-
isothermal TG of polymorphs I and II of rifampicin, the 
Ozawa’s method available in the software of the thermal 
analysis system TA 50-WS (Shimadzu) was applied. For 
application of this method  the obtainment of at least three 
TG curves under different heating rates are required. In 
this study, five TG curves were obtained at a β of 2.5, 5, 
7.5, 10, 15 and 20 °C/min.
The overlapping of these TG curves of the polymor-
phs I and II are illustrated in Figure 5a and 5b, respectively. 
Ozawa’s method was applied to data obtained from the 
five TG curves to determine the E
a
 at the beginning of the 
first event of mass loss, corresponding to the process of 
thermal decomposition that occurs for the polymorph I 
between 240 and 270 °C, and for the polymorph II between 
180 and 210 °C.
For higher heating rates the thermal events are shif-
ted to higher temperatures. Figures 6a and 6b correspond 
to the heating rates logarithm versus the inverse absolute 
temperature (Log β vs 1/T), obtained after the processing 
of data by Ozawa’s method, which allowed the kinetic 
parameters [the activation energy (E
a
), reaction order 
(n) and frequency factor (A)] listed in Table I to be 
obtained for polymorphs I and II. These results confirm 
the greater stability of polymorph I in comparison with 
polymorph II.
FIGURE 4 - DSC curves obtained at 10 oC/min for the rifampicin 
samples: (a) polymorph I and (b) polymorph II.
FIGURE 5 - TG curves obtained under dynamic air atmosphere and with different heating rates for the rifampicin samples: (a) 
polymorph I and (b) polymorph II.
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Thermal decomposition kinetics of polymorphs I 
and II by isothermal TG
The isothermal method is commonly used to monitor 
the reaction kinetics of thermal decomposition in solid sta-
te: several plots are obtained of fraction decomposed (Dm) 
versus time (t), keeping the constant temperature (T) in the 
region of interest. The isothermal kinetic method shows 
that the main difference to the dynamic or non-isothermal 
method is the possibility of performing measures of Dm 
as a function of time. In the dynamic kinetic study, the 
heating rate is used as a variable to obtain each one of the 
thermogravimetric curves. However, in the isothermal stu-
dy, the heating rate is always the same and the temperature 
of the isotherms are varied, and therefore decomposition 
time is estimated for a defined range of mass loss.
A disadvantage presented by the isothermal method 
in comparison with the dynamic method, is the relatively 
long time usually required for data acquisition. The cal-
culation of the activation energy is based on the Arrhenius 
equation (Equation 4).
The data presented in Figures 7 and 8 show the 
process of obtaining the values of E
a
 using the isothermal 
method for samples of rifampicin (polymorphs I and II). 
TABLE I - Kinetic parameters for the rifampicin polymorphs 
I and II obtained from the kinetic treatment data of thermal 
decomposition for non-isothermal TG
   
Sample Kinetic Parameters
E
a
 (kJ/mol) n A (min-1)
Polymorph I 154 0 1,73x1014
Polymorph II 123 1 3,50x1012
FIGURE 6 - Logarithimic curves of heating rate as a function of inverse of absolute temperature of the rifampicin samples: (a) 
polymorph I and (b) polymorph II.
FIGURE 7 - TG curves obtained under isothermal conditions and dynamic air atmosphere (50 mL. min-1) for the rifampicin samples: 
(a) polymorph I and (b) polymorph II.
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For polymorph I, the TG curves (Figure 7a) were obtained 
by heating the sample at 200, 205, 210, 220 and 230 °C 
and maintained at isothermal conditions under a dynamic 
atmosphere of air (50 mL min-1) for a sufficient time for 
the mass loss to be at least 10%. For polymorph II, the TG 
isotherm curves (Figure 7b) were obtained at temperatures 
of 175, 180, 185, 190 and 195 °C. These curves show the 
dependence of the mass loss, according to isotherm tem-
perature: it is evident that the higher the temperature, the 
lower the time necessary for the same mass loss to occur. 
Differences can be seen in the profile of the isothermal TG 
curves between the samples. It was observed that under 
conditions in which these curves have been obtained, the 
mass loss for the polymorphic form I occurred more rapidly.
Figures 8A and 8B show the plots of ln t (min) vs 
1/T (K), respectively, for polymorphs I and II, from which 
straight line equations were obtained which correspond 
to linear regression (y = ax + b). The slope of the line is 
defined by a (slope), and the E
a
 can be determined by mul-
tiplying a by the general gas constant R (8.314 J mol-1 K-1). 
The values of E
a
 were 137 and 144 kJ mol-1, respecti-
vely, for polymorphs I and II, respectively. The comparison 
between the values of E
a
 found for both methods of evalu-
ation of the kinetics of thermal decomposition showed a 
distortion. This distortion can be explained by the possibility 
of transformation of polymorphic form II into polymorphic 
form I. As in the isothermal method, the data were obtained 
at temperatures close to those at which the material under-
goes melting and recrystallization processes, and favors the 
formation of a mixture of polymorphs i.e., during the time of 
the heating at the temperature of the isotherm, the formation 
of polymorph I may partly occur, which certainly modified 
the characteristics of the sample under evaluation.
In a bid to understand the thermal behavior of 
polymorph II and confirm its subsequent transformation 
into polymorph I, after the processes of melting and re-
crystallization, the samples of material were heated and 
maintained at specific isothermal temperatures for 45 
minutes. The intermediate products obtained at isotherm 
temperatures of 170, 190, 200 and 210 oC were isolated 
for characterization by infrared spectroscopy (IR). One 
sample was also collected after being kept isothermal for 
10 minutes at 200 oC.
The IR spectra of the products collected after heating 
polymorph II at different temperatures were recorded in 
the range of wavenumber 4000-400 cm-1. These spectra are 
illustrated in Figure 9 along with the spectra of polymorphs 
I and II. From these spectra it was concluded that up to 
170 oC the polymorph II did not undergo any structural 
changes. However, the IR spectrum of product isolated at 
190 oC is characteristic of polymorphic form I, as occurred 
with the spectrum of product isolated after 10 minutes 
of heating at 200 oC. This heating time of 10 minutes is 
more appropriate to detect the structural change, since at 
45 minutes in T
isothermal
 , partial thermal decomposition of 
the material already takes place. Figure 10 illustrates the 
isothermal TG curve at 190 oC. It may be noted that there 
was a mass loss of about 2.3% of polymorph II after 45 
minutes of heating, confirming the partial thermal decom-
position of this species.
CONCLUSIONS
The studies performed using TG/DTG and DSC tech-
niques revealed a significant difference between the thermal 
stability of the polymorphic forms I and II of rifampicin, 
which may be important for drug/excipient compatibility 
and consequently for the stability of the formulated pro-
ducts. Polymorph II is the metastable form, as shown on 
the DSC curve, due to melting followed by recrystalliza-
FIGURE 8 - Arrhenius plot, ln t vs 1/T, for thermal decomposition of the rifampicin samples: (a) polymorph I and (b) polymorph II.
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FIGURE 9 - IR spectra of the polymorph I, polymorph II and 
intermediate products isolated from polymorph II at different 
temperatures with isotherm time: (a) 10 minutes and (b) 45 
minutes. 
FIGURE 10 - Isothermal TG curve at 190 oC of the polymorph 
II sample.
tion as polymorph I. The E
a
 obtained from 154 kJ/mol for 
polymorph I and 123 kJ/mol for polymorph II by using 
the Ozawa method are consistent with the higher thermal 
stability expected for polymorph I. The E
a
 of 137 and 
144 kJ/mol for polymorphs I and II, respectively, determi-
ned by isothermal methods, showed distortions. The value 
of E
a
 for polymorph I was expected to be higher than that 
in polymorph II. This difference may be explained by the 
metastable characteristic of polymorph II, and because 
heating in the T
isotherm
 is close to its melting point, its partial 
conversion occurs in the polymorph I. Thus, the results cor-
respond to a mixture of polymorphs, and probably a product 
of partial thermal decomposition of the species. The use of 
different polymorphs in a particular design requires care, 
since this can lead to the production of medicines which 
are not equivalent due to differences in solubility between 
them. Also, the conversion of one polymorph to another can 
occur, as can their interaction with inert excipients of the 
medicine during processing and/or storage.
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